Previous studies have shown that the human melanoma differentiation-associated gene-7 (mda-7)/interleukin-24 (IL-24) has tumorsuppressor activity in vitro and in vivo. Additionally, in vitro studies using human peripheral blood mononuclear cells indicate that mda-7/IL-24 has TH1 cytokine-like activity. However, the individual properties of mda-7/IL-24 have been previously examined separately. Thus, there is not a single study that has examined both, antitumor and proimmune properties of mda-7/IL-24. Furthermore, the tumor suppressive activity and the cytokine activity of mda-7/IL-24 have not been previously tested in an immunocompetent setting. We therefore in the present study evaluated the antitumor and immune properties of mda-7/IL-24 in a murine syngeneic tumor model. In vitro, adenovirus-mediated mda-7 gene (Ad-mda7) transfer to murine fibrosarcoma (UV2237m; MCA16) and normal (10T1/2) cells significantly inhibited growth (P ¼ 0.001) and induced apoptosis in tumor cells but not in normal cells. In vivo, intratumoral administration of Ad-mda7 resulted in significant inhibition of tumor growth (Po0.05), with a subset of mice showing complete tumor regression. We next evaluated the immune potentiation activity of Ad-mda7 in a cancer vaccine model. UV2237m cells transfected with Ad-mda7 and injected into syngeneic immunocompetent C3H mice were unable to grow; however, they did grow in immunocompromised nude mice. These tumor-free C3H mice, when challenged with parental tumor cells experienced no tumor growth, suggesting induction of systemic immunity. Moreover, splenocytes prepared from vaccinated C3H mice demonstrated higher proliferative activity and produced elevated levels of TH1 cytokines compared with those from control mice. An in vitro subset analysis of splenocytes from vaccinated mice demonstrated a significant increase in the CD3 þ CD8 þ but not the CD3 þ CD4 þ cell population (P ¼ 0.019). Thus Ad-mda7 treatment of syngeneic tumors induces tumor cell death and promotes immune activation, leading to anticancer immunity.
Introduction
Cancer is one of the leading causes of death in the world. The molecular mechanisms for cancer development and progression are due to multiple defects in a cell that include gene alterations, gene silencing, receptor rearrangements and alterations in the cell signaling pathways. 1 Apart from these changes, growth factors produced by the tumor cells alter the tumor microenvironment resulting in functional inactivation of host-immune cells and host immunity. 2 Thus, to overcome these limitations novel gene therapy-based approaches are being tested that include reintroduction of tumor-suppressor genes for suppressing tumor growth 3, 4 and expression of cytokine genes that elicit active immune response against the growing tumor. 5, 6 Although several tumor-suppressor genes have shown promise in preclinical studies, only a few of them have been tested in the clinic and have had limited success. 7, 8 Immunotherapeutic approaches using tumor cells that are genetically modified with cytokine (IL-2, IL-4, interferon (IFN)-g, IL-12 and granulocytemacrophage colony-stimulating factor (GM-CSF)) genes have had success in cancer therapy. 9, 10 However, the antitumor activity exhibited by these cytokine genes relies on stimulating the immune function and have no direct tumor suppressive activity. Furthermore, there is a potential for cytokine-induced toxicity. 11 Thus, there is a continuous effort to identify and test new therapeutic genes that can function both as a tumor suppressor and as a cytokine gene. A gene that has both, tumor suppressor and cytokine property will overcome the existing limitation and will be an effective cancer drug.
The human melanoma differentiation-associated gene-7 (mda-7)/interleukin-24 (IL-24) is a novel tumor suppressor/cytokine gene that belongs to the IL-10 cytokine superfamily. 12 Studies by us and others have previously shown that mda-7/IL-24 has potent antitumor activity in a broad spectrum of human cancer cells both in vitro and in vivo. [13] [14] [15] Furthermore, we and others have previously shown that mda-7-expressing cells secrete the protein and that the secreted mda-7 protein has 'bystander' antitumor and antiangiogenic activity. [16] [17] [18] In addition to it's antitumor and antiangiogenic activity, the mda-7 protein has been reported to have TH1 cytokine-like activity. 19 In the study by Caudell et al., 19 treatment of human peripheral blood mononuclear cells (PBMCs) with mda-7/ IL-24 protein resulted in the secretion of IL-6, IFN-g, tumor necrosis factor (TNF)-a and IL-12 and has been proposed as a novel pro-TH1-type cytokine. Based on these in vitro results, it was concluded that the TH1 cytokine-like activity of secreted mda-7 protein can promote or induce host immunity and may play a role in suppressing tumor growth. Thus the proimmune activity of mda-7/IL-24 in combination with its antitumor activity will be effective as a cancer drug.
Although in vitro studies showed the proimmune activity for mda-7/IL-24 there are no in vivo studies demonstrating the TH1 cytokine-like activity for mda-7/ IL-24. Furthermore, all of the in vivo studies reported previously were carried out using immunodeficient nude mouse xenograft tumor models. 15, 20, 21 A major limitation of using these nude mouse models is that the contribution of mda-7/IL-24 as proimmune cytokine in suppressing tumor growth cannot be studied. We therefore tested the antitumor activity of human mda-7/IL-24 in an immunocompetent setting using murine syngeneic tumor models both in vitro and in vivo and found that treatment of murine tumor cells with adenoviral vector expressing the mda-7/IL-24 gene (adenovirus-mediated mda-7 (Ad-mda7)) induced apoptotic cell death and promoted immune activation, leading to systemic antitumor immunity.
Materials and methods

Animals and cell lines
We used 6-8-week-old C3H/HeN female mice (National Cancer Institute-Frederick Cancer Research Facility, Frederick, MD) and athymic nude mice (Charles River Laboratories, Wilmington, DE). The mice were purchased and used in the present study. The mice were kept under specific pathogen-free conditions and handled per institutional guidelines.
The C3H/MCA clone 16 (MCA16) fibrosarcoma cell line and 10T1/2 fibroblast cell lines were purchased from the American Type Culture Collection (Rockville, MD). The UV2237m fibrosarcoma cell line was provided by Dr Isaiah J Fidler. 22 The cells were maintained as a monolayer culture in Dulbecco's modified Eagle's medium containing high glucose and supplemented with 10% fetal bovine serum (FBS) (GIBCO-BRL, Grand Island, NY), nonessential amino acids (GIBCO-BRL) and L-glutamine (GIBCO-BRL).
Adenovirus construction
Construction and production of replication-deficient adenovirus vector (Ad5) carrying the mda-7 or luciferase (luc) gene has been previously described. 12, 16 Briefly, Ad5 vector carrying the mda-7 (Ad-mda7) or luc (Ad-luc) gene linked to an internal CMV-IE promoter followed by SV-40 polyadenylation signal were constructed. Adenovirusmediated mda-7 and Ad-luc viruses were propagated in 293 cells, purified by column chromatography and characterized by testing for optical density as a measure of number of viral particles (vp) and plaque-forming units (pfu) as a measure of infectivity. The ratio of the number of vp to pfu was 20 (20 vp ¼ 1 pfu).
Cell proliferation assay
We have previously used Ad-mda7 at an infectivity of 2000-3000 vp per cell (vp/cell) for human cancer cells. 12, 13, 15, 16 However, the infectivity and efficiency in murine cancer cells is not known. Therefore, prior to start of the experiments, murine tumor and normal cell lines were treated with Ad-GFP with 1000, 2000, 3000, 5000, 7500 and 10 000 vp/cell and the efficiency of transfection determined by flow cytometry. Cells infected with 10 000 vp/cell showed maximum transfection approaching approximately 75% while cells transfected with 3000 vp/ cells showed approximately 10-15% transduction (data not shown). Based on these preliminary results, Ad-mda7 or Ad-luc (control vector) at a concentration of 10 000 vp/ cell was used in all the in vitro experiments described below.
To determine the effect of Ad-mda7 on cell proliferation, murine tumor (UV2237m, MCA16) and normal (10T1/2) cells plated in six-well plates (10 5 cells/well) were treated with Ad-luc or Ad-mda7 (10 000 vp/cell) in triplicates. Cells that did not receive any treatment served as control. Cells were harvested on days 1-5 after infection and analyzed for cell viability by trypan blue exclusion assay method as previously described. 13 Experiments were performed three separate times and results represented as the average mean of three experiments.
Western blot analysis Cells (UV2237m, MCA16 and 10T1/2) were treated with Ad-mda7 or Ad-luc (10 000 vp/cell) as described above. At 48 h after treatment cells were harvested, cell lysates prepared and subjected to Western blotting. 13 Cells that 
In vivo experiments
To determine the therapeutic effect of Ad-mda7 against murine tumors in vivo, subcutaneous tumors were established by injecting UV2237m cells (1 Â 10 6 ) in the lower right dorsal flank of C3H/HeN mice. 23 When the tumor size reached 50-100 mm, 3 animals were randomized into three groups and treated as follows: group 1 (n ¼ 10) was treated with phosphate-buffered saline (PBS); group 2 (n ¼ 10) was treated with Ad-luc and group 3 (n ¼ 10) was treated with Ad-mda7. Ad-luc and Ad-mda7 were administered intratumorally three times a week for a total of six doses (1 Â 10 10 vp/dose; Introgen Therapeutics Inc., Houston, TX). Tumor measurements were recorded as described previously. 15, 23 Animals were euthanized by CO 2 inhalation when the tumor size reached 1.0 cm or showed extensive ulceration. Animals that showed complete tumor regression were monitored for an additional 30 days and later euthanized.
To determine the tumorigenicity of Ad-mda7-infected tumor cells in vivo, UV2237m cells were infected with Ad-luc or Ad-mda7 (10 000 vp/cell) and incubated at 371C. At 24 h after infection, cells were washed two times with PBS, counted, and resuspended at a concentration of 5 Â 10 6 cells/ml in PBS. C3H mice (n ¼ 30) or nude mice (n ¼ 30) were divided into groups (n ¼ 10/group) and were subcutaneously injected with 200 ml of this suspension (1 Â 10 6 cells per animal). Mice (n ¼ 10) that were implanted with parental tumor cells served as controls. Tumor formation was monitored every other day after injection as previously described. 15, 23 To determine the protective effects of mda-7/IL24 as a cancer vaccine, mice were subcutaneously injected with parental UV2237m cells (n ¼ 10) or Ad-mda7-infected UV2237m cells (n ¼ 10; 1 Â 10 6 cells per animal) and monitored for tumor growth. Mice (n ¼ 10) that did not experience tumor formation were given parental UV2237m (1 Â 10 5 per mouse) at 24-28 days after vaccination in the flank opposite the previous vaccination site and compared with treatment of naive mice (n ¼ 10) injected with the same number of parental tumor cells. Tumor growth was monitored every other day as described previously. 15, 23 Differences in the development of tumors and tumor volumes were determined between untreated naive mice and Ad-mda7-treated mice and were analyzed for statistical significance.
Splenocyte preparation and culture conditions Splenocytes were prepared as previously described. 24 In brief, mice were killed 10 days after implantation of tumor cells transfected with Ad-mda7 or Ad-luc. Spleens from these euthanized mice (n ¼ 3/group) were minced with scissors and gently ground between two ground glass slides. The cell suspension was passed through a cell strainer (70 mm nylon; Beckton-Dickinson, Franklin Lakes, NJ) one time, and a mononuclear cell fraction constituting the splenocytes was collected after density centrifugation with Histopaque s -1077 (Sigma-Aldrich, St Louis, MO). Splenocytes were washed three times in Hank's balanced salt solution (MD Anderson Cancer Center Core Laboratory, Houston, TX) and immediately used for cell proliferation, cytokine production or subset analyses as described below. Cells were otherwise cultured in RPMI-1460 medium containing 10% FBS, 5 Â 10 À5 M 2-mercaptoethanol (Sigma Chemicals), 1% sodium pyruvate (GIBCO-BRL), 1% NEAA, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml of streptomycin (GIBCO-BRL).
Flow cytometry
To assess whether vaccination with Ad-mda7-infected tumor cells promotes in vivo antitumor reactivity, splenocyte cell proliferation was determined by comparing the percentage of each round of dividing daughter splenocytes using carboxyfluorescein acetate succinidyl ester (CFSE). 25, 26 Splenocytes prepared from the spleens of mice that had been injected with Ad-mda7-infected UV2237m tumor cells (n ¼ 3) were compared with those prepared from mice injected with Ad-luc-infected UV2237m cells (n ¼ 3) and those from untreated naive mice (n ¼ 3) on day 10. Freshly prepared splenocytes were labeled using the Vybrant CFDA SE cell tracer kit (Molecular Probes, Eugene, OR) following the manufacturer's instructions and were seeded in 48-well plates (2 Â 10 6 cells/well). Labeled cells were added to culture wells containing irradiated tumor cells. After incubation for 6 days, splenocytes were harvested and analyzed with a FACSCalibur flow cytometer (BD Biosciences, Mountain View, CA). The kinetics of the proliferating large lymphocyte population as measured by CFSE fluorescence was determined, and the data were analyzed using Cell Quest software (BD Biosciences).
For phenotypic characterization of the lymphocyte subpopulation, splenocytes from mice that had been vaccinated with Ad-mda7-infected UV2237m tumor cells (n ¼ 3) and from mice that had been vaccinated with Ad-luc-infected UV2237m cells (n ¼ 3) were prepared by euthanizing mice on day 10 as described above. Splenocytes from untreated naive mice (n ¼ 3) were used as control. Freshly prepared splenocytes (1 Â 10 6 ) were analyzed for surface markers using monoclonal antibodies fluorescein isothiocyanate-conjugated anti-CD3e, phycoerythrin-conjugated anti-CD4 (L3T4), allophycocyanine-conjugated anti-CD8a (Ly-2) (eBioscience, San Diego, CA). After incubation with the primary antibody for 1 h, cells were washed three times with flow cytometry buffer, fixed in 1% paraformaldehyde, and analyzed with FACSCalibur flow cytometer. Data were recorded and analyzed using Cell Quest software. The analysis was performed by gating cells using forward and side scatter characteristics.
mda-7/IL-24-mediated anticancer immunity R Miyahara et al Measurement of cytokines secreted into culture supernatant To measure cytokine secretion from lymphocytes, mice vaccinated with Ad-luc-infected UV2237m cells (n ¼ 3) and the mice vaccinated with Ad-mda7-infected UV2237m cells (n ¼ 3) were euthanized on day 10 after tumor cell implantation. Splenocytes from the spleens of these mice were prepared as described above and were seeded in a 48-well plate (2 Â 10 6 cells/well) containing irradiated UV2237m cells (1 Â 10 5 cells/well, effector: target ratio ¼ 20:1) for 6 days. Splenocytes prepared from untreated naive mice (n ¼ 3) served as controls. Culture medium was collected and replenished every other day for 6 days. The collected supernatants were pooled and stored at À201C. Two milliliters of the supernatant from each sample was concentrated into 200 ml using a Centriplus YM-10 concentrator (Millipore Co., Bedford, MA). The amount of secreted cytokines (TNF-a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, GM-CSF, IFN-g) in the concentrated samples was measured using Luminex 100 (Luminex Co., Austin, TX) after the samples had been prepared with mouse cytokine 10-Plex (Biosource, Camarillo, CA) according to the manufacturer's instructions. Samples were analyzed in triplicate, and the mean results are reported.
Statistical analysis
All of the experiments were performed two times and analyzed for statistical significance. In vitro experiments were analyzed by Student's t-test and analysis of variance (ANOVA). In in vivo experiments, differences in tumor volumes were determined by Student's t-test; differences in time taken to form tumors were determined by the logrank test using SPSS software (SPSS Inc., Chicago, IL).
Results and discussion
Adenovirus-mediated mda-7 inhibits murine tumor cell growth by inducing apoptosis Studies by us and others have previously demonstrated the antitumor activity of human mda7/IL-24 against a broad spectrum of human cancer cell lines. [12] [13] [14] [15] However, information related to the antitumor activity of human mda-7/IL-24 in murine tumor cells is limited. We therefore first determined whether Ad-mda7 expression (Admda7) could induce growth suppression and apoptosis in murine tumor (UV2237m and MCA16) and normal fibroblast (10T1/2) cell lines. A significant inhibition of proliferation (P ¼ 0.001) was observed in both tumor cell lines (66-75%) treated with Ad-mda7 compared with that in cells treated with PBS or Ad-luc (Figure 1a) . In UV2237m, Ad-luc-treated cells also showed significant growth inhibition compared to PBS-treated cells (Figure 1a) . However, the Ad-luc-mediated inhibitory effect was less compared to Ad-mda7-mediated inhibitory effect in these cells. The induction of G2/M cell cycle arrest in Ad-mda7-treated cells was associated with tumor growth inhibition (data not shown). In normal cells, treatment with Ad-mda7 showed no significant growth inhibition compared with treatment with PBS or Ad-luc (Figure 1a) . Furthermore, G2/M cell cycle arrest was not observed in Ad-mda7-treated normal cells (data not shown).
Activation of the caspase cascade in Ad-mda7-treated human cancer cells has previously been demonstrated. 13, 16 On the basis of these findings we examined the mechanism by which Ad-mda7 induced apoptosis in murine tumor cells. Activation of caspase-3, cleavage of PARP, and cytochrome C release into cytoplasm was observed in all, PBS-, Ad-luc-and Ad-mda7-treated tumor cells (Figure  1b and c) . Activation of caspase-3, PARP and cytochrome C in PBS-and Ad-luc-treated cells were however, less compared to Ad-mda7-treated cells. The detection of transgenic mda-7 was related to the caspase activation in tumor cells. Activation of caspase-3 and cleavage of PARP were not observed in 10T1/2 cells although MDA-7 protein was detected in Ad-mda7-treated cells (Figure 1b) . Furthermore, caspase-3 and PARP cleavage were not observed in PBS-or Ad-luc-treated 10T1/2 cells. We did not test for cytochrome C release in these cells because we did not observe any sensitization to Ad-mda7. These results show that overexpression of human mda-7 in murine tumor cells inhibits tumor cell proliferation and induces apoptosis, a phenomenon similar to that observed in human cancer cells.
We next assessed the therapeutic effects of intratumoral injection of Ad-mda7 on UV2237m subcutaneous tumors established in syngenic C3H mice. Injection of Ad-mda7 significantly delayed tumor growth compared with tumor growth in mice treated with PBS (days 6, 8, 10, 12) or Adluc (days 14, 16, 18, 20) (Po0.05) (Figure 1d ). Furthermore, analysis of tumors to reach a size of 400 mm 3 in this experiment showed that tumors in PBS-treated control animals required an average mean of 6 days, whereas tumors in Ad-luc-treated animals required an average mean of 10 days (Figure 1d ). In contrast tumors in Ad-mda7 treated mice showed an average mean of 20 days to reach a size of 400 mm 3 indicating a delay by 14 days compared with that in PBS-treated animals. Additionally, tumors in a fraction of Ad-mda7-treated mice showed complete and prolonged regression (data not shown). Although the ability of Ad-mda7 to inhibit murine tumor growth in vivo is similar to that observed when using human tumor xenografts, our current experimental design provided an opportunity to conduct therapeutic studies in an immunocompetent model. Furthermore, to our knowledge, this is the first report demonstrating the direct tumor inhibitory activity of Admda7 in a syngeneic mouse tumor model.
Vaccination with adenovirus-mediated mda-7-infected tumor cells induces systemic antitumor immunity
Since a subset of animals experienced complete tumor regression in the efficacy studies, we investigated the effects of Ad-mda7 in a tumor vaccine model. In a prophylactic tumor vaccine strategy, a concentrated local expression of inflammatory cytokines needs to be achieved to boost the immune response against the tumor. 27 As the mda-7 protein has been shown to be mda-7/IL-24-mediated anticancer immunity R Miyahara et al secreted from cells expressing mda-7 and that the secreted mda-7 protein to have TH1 cytokine function we hypothesized that Ad-mda7 treatment of tumors would result in local mda-7 protein secretion, thereby inducing or promoting systemic antitumor immunity. Before testing this hypothesis we evaluated the ability of Admda7-transduced tumor cells to produce mda-7 protein in vitro. Western blotting showed secretion of mda-7 protein by Ad-mda7-infected tumor cells (Figure 2a) . Furthermore, mda-7 protein expression was detectable for at least 7 days in both cell lysate and supernatant, validating the use of mda-7 protein-expressing tumor cells as a vaccine.
On the basis of these in vitro results, we subcutaneously injected C3H and nude mice with UV2237m cells that were either not infected (control) or infected with Ad-luc or Ad-mda7 ex vivo, and then we monitored tumor growth. Tumor growth was completely inhibited in 100% of C3H mice that were injected with Ad-mda7-infected tumor cells but not in control mice and mice injected with Ad-luc-infected tumor cells (Po0.01) (Figure 2b ). Control C3H mice and mice treated with Ad-luc-treated tumor cells had similar tumor growth kinetics and all of these animals developed tumors. In nude mice unlike C3H mice, injection of Ad-mda7-infected tumor cells resulted in tumor formation albeit, at a lower growth rate than in mice that had been implanted with uninfected tumor cells or Ad-luc-infected tumor cells (Figure 2c ). These results show that Ad-mda7 treatment suppresses tumor growth in both C3H and nude mice. However, for complete and effective tumor inhibition as observed in the C3H mice a functioning immune system is needed. These results further support the findings of Caudell et al. 19 and suggest that mda-7 may stimulate or promote immunomodulatory functions. We next evaluated whether C3H mice that had been implanted with Ad-mda7-infected tumor cells and were tumor free had developed systemic immunity. For this purpose, the tumor-free C3H mice were given parental UV2237m cells (injected on the contralateral side) and compared with treatment-naive mice for their formation of tumors. As shown in Figure 2d , long-term tumor-free survival was observed in 65% of mice that had been vaccinated with Ad-mda7-infected tumor cells (P ¼ 0.002); a subset of these animals developed tumors after 22 days. In treatment-naive mice, tumor-free survival was not observed, as all the mice developed tumors within 6 days after implantation. Furthermore, comparison of the tumor growth curves in vaccinated mice and in treatment-naive mice demonstrated a significant delay in tumor growth in the former group (Po0.001) (Figure 2e ). These results indicate that vaccinating mice with Ad-mda7-infected tumor cells protects them from tumor growth upon contralateral challenge, and likely because of induction of systemic immunity.
The exact mechanism by which mda-7/IL-24 induces systemic immunity remains to be studied. One possibility is that mda-7/IL-24-mediated tumor cell apoptosis results in immunogenic apoptotic bodies that are efficiently taken up by antigen presenting cells for presentation to T cells. Another possibility is that the secreted mda-7 protein activates immune accessory and effector cells present within the tumor microenvironment and at distant sites leading to systemic immunity. We are currently investigating these possibilities in our laboratory.
Proliferating splenocytes from vaccinated animals produce TH1 cytokines To determine whether the tumor protective effects observed in vaccinated mice was due to systemic immunity, we analyzed splenocytes from these mice for their ability to proliferate and produce cytokines. Freshly harvested splenocytes from mice vaccinated with Admda7-infected tumor cells had a higher proliferative rate in vitro than did splenocytes from treatment-naive mice and from mice vaccinated with Ad-luc-infected tumor cells (Figure 3a) . The increased proliferative rate of cells from mice vaccinated with Ad-luc-infected tumor cells could be due to immune recognition of the foreign luciferase protein or adenoviral vector proteins. 28 We next investigated the ability of proliferating splenocytes to produce proinflammatory cytokines. Cultured supernatants from splenocytes of treatment-naive mice and vaccinated mice were analyzed for cytokine induction. As shown in Figure 3b , a significant (Po0.01) increase in TNF-a, GM-CSF, and IL-6 levels were observed in the culture medium of proliferating splenocytes from Ad-mda7-vaccinated mice compared with those from treatment-naive mice or Ad-luc-vaccinated mice. A significant (Po0.01) increase in IL-6 was also observed in Ad-luc-vaccinated mice compared to those from treatment-naive mice. Analysis of IFN-g showed that splenocytes from both Ad-mda7-and Ad-lucvaccinated mice induced much higher IFN-g secretion than did no treatment (Figure 3b) . Although the IFN-g levels was increased in both Ad-mda7-and Ad-lucvaccinated mice, the level of IFN-g secretion was much higher in the culture supernatant of proliferating splenocytes from Ad-mda7-vaccinated mice (509.49 pg/ml) than in Ad-luc-vaccinated mice (393.74 pg/ml). Our results demonstrate increased levels of TNF, IFN-g, GM-CSF and IL-6 in the splenocytes collected from mice that were implanted with Ad-mda7-treated cells. Thus, mda-7 protein produced following Ad-mda7 treatment results in the induction of Th1 cytokine production. These observations concur with those of Caudell et al. 19 who found induction of TH1 cytokines when human PBMCs were treated with purified human mda-7 protein. Production of IFN-g, TNF-a and IL-6 was also reported in the serum of patients who were treated with intratumoral injection of Ad-mda-7. 28 We next investigated lymphocyte phenotypes in the proliferating splenocytes. Analysis for CD3 þ CD4 þ and CD3 þ CD8 þ cells showed that no significant difference in the number of CD3 þ CD4 þ cells between treatmentnaive, Ad-luc-and Ad-mda7-vaccinated mice (Figure 3c ). However, a significant increase in CD3 þ CD8 þ cells was observed in Ad-mda7-vaccinated mice compared with that in treatment-naive and Ad-luc-vaccinated mice (P ¼ 0.019) (Figure 3c ). Furthermore, in vitro stimulation of splenocytes with irradiated tumor cells induced a significant increase in CD3 þ CD8 þ cells from Ad-mda7-vaccinated mice compared with those from treatmentnaive and Ad-luc-vaccinated mice (data not shown). These results suggest that Ad-mda7 treatment in a therapeutic or prophylactic setting increases systemic TH1 cytokine production and mobilizes CD8 þ T cells leading to systemic anticancer immunity. Although an increase in CD3 þ CD8 þ T cells was observed in the present study, the exact function of these cells remains to be determined and is currently under investigation in our laboratory. The ability of Ad-mda7 vaccination of mice to stimulate splenocyte proliferation, predominantly of the CD3 þ CD8 þ type is in agreement with the results from a recently concluded clinical trial. 29 In that study, patients given an intratumoral injection of Ad-mda7 (INGN241) experienced a marked increase in CD3 þ CD8 þ T cells after treatment. Thus mda-7/IL-24 unlike IL-10 functions as a TH1-type cytokine. Our data strongly suggest that because of its antitumor, antiangiogenic and immune properties, Ad-mda7 is a potent anticancer drug.
Although we in the present study have shown the immune properties of mda-7 in a prophylactic and cancer vaccine setting using Ad-mda7, it is to be noted that there are potential drawbacks in its application in a clinical setting: First, ex vivo transduction of human cancer cells obtained from cancer patients with Ad-mda7 followed by reintroduction into cancer patients is not practical; second, intratumoral administration of Ad-mda7 to generate a potent antitumor immune response is applicable only to localized tumors and not for disseminated tumors. Thus, alternate approaches need to be developed for mda-7 testing as a vaccine.
In conclusion, our data demonstrate that Ad-mda7 treatment of syngeneic tumor models results in tumor growth inhibition leading to anticancer immunity. In addition our results provide a basis for future mda-7/ IL-24-based immunologic and immunotherapy studies.
